Skip to content
Homepage
Author:
Nurix Therapeutics, Inc.
Posted Date:
July 22, 2026
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics, Inc.
July 22, 2026
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Nurix Therapeutics, Inc.
July 9, 2026
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Nurix Therapeutics, Inc.
June 11, 2026
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics, Inc.
June 8, 2026
